Grant: CIHR Fellowship
Direct Payment
$150,000.00
Sensory neuron silencing reverses allergic airway inflammation
FY 2013-14
Summary
Asthma is a chronic inflammatory disease of the airway characterized by reduced airflow and affects more than 300 million patients worldwide. Although bronchodilators and steroids control disease symptoms and can abort attacks, children with severe asthma have frequent, poorly controlled attacks and excessive morbidity. While the role of the nervous system in modulating inflammation is increasingly recognized, it is uncertain whether the lung sensory fibers that cause cough (in response to inhaled irritants) also contribute to asthma. We have discovered a method to selectively block electrical activity in lung pain-sensing fibers by using permanently charged derivatives of sodium channel blockers (similar to the local anesthetic lidocaine), which act inside of nerve fibers by binding to a specific site on sodium channels. To access this site, the blockers must diffuse through the neuronal membrane. Charged drugs are normally unable to move through the hydrophobic cell membranes, but we have discovered that small charged sodium channel blockers can enter cells through large pore ion channels that are found exclusively on pain fibers. When open, these pores essentially act as a local drug delivery device. We have also shown that the large pore channels present on lung sensory fibers allow a permanently charged form of lidocaine, called QX-314, to enter and silence lung pain fibers. In a mouse asthma model, we find that such silencing markedly reduces immune cell infiltration, resistance to air passage, and mucus secretion, with an even greater efficacy than high dose steroids. These data show that sensory fibers act upstream of the immune cells that produce allergic airway inflammation, and thus represent a novel therapeutic target. Proposed future experiments will now uncover exactly how sensory fibers act on immune cells to cause airway inflammation.
Department
Program
CIHR Fellowship
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
301064
Name
Talbot Sébastien
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Sensory neuron silencing reverses allergic airway inflammation
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Asthma; Chronic Neurogenic Inflammation; Flow Cytometry; Local Anesthetic; Neuro-Immunology; Neuropeptide; Qx-314; Rna-Seq; Sensory Neurons; Trpv1/Trpa1 Channel
Abstract
Asthma is a chronic inflammatory disease of the airway characterized by reduced airflow and affects more than 300 million patients worldwide. Although bronchodilators and steroids control disease symptoms and can abort attacks, children with severe asthma have frequent, poorly controlled attacks and excessive morbidity. While the role of the nervous system in modulating inflammation is increasingly recognized, it is uncertain whether the lung sensory fibers that cause cough (in response to inhaled irritants) also contribute to asthma. We have discovered a method to selectively block electrical activity in lung pain-sensing fibers by using permanently charged derivatives of sodium channel blockers (similar to the local anesthetic lidocaine), which act inside of nerve fibers by binding to a specific site on sodium channels. To access this site, the blockers must diffuse through the neuronal membrane. Charged drugs are normally unable to move through the hydrophobic cell membranes, but we have discovered that small charged sodium channel blockers can enter cells through large pore ion channels that are found exclusively on pain fibers. When open, these pores essentially act as a local drug delivery device. We have also shown that the large pore channels present on lung sensory fibers allow a permanently charged form of lidocaine, called QX-314, to enter and silence lung pain fibers. In a mouse asthma model, we find that such silencing markedly reduces immune cell infiltration, resistance to air passage, and mucus secretion, with an even greater efficacy than high dose steroids. These data show that sensory fibers act upstream of the immune cells that produce allergic airway inflammation, and thus represent a novel therapeutic target. Proposed future experiments will now uncover exactly how sensory fibers act on immune cells to cause airway inflammation.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Talbot, Sébastien
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~